Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.
- March 31, 2023
Sepsis committees are chartered with introducing new technologies and processes to treat patients with the right therapies more quickly. The inclusion of T2Direct Diagnostics™ in a hospital’s sepsis protocol can enable faster time to targeted therapy, improved patient outcomes, and de-escalation of antimicrobial drug use.
The T2Direct Diagnostics family of tools provides rapid and accurate results directly from whole blood in 3 to 5 hours. These tools can identify the most serious bacterial and fungal pathogens often not responsive to first-line empiric therapy.
The T2Bacteria® and T2Candida® Panels are the only FDA-cleared and CE-marked diagnostics that provide species identification for some of the most common and deadly sepsis-causing pathogens – without having to wait 1 to 5 days or more for blood culture results. Early targeted therapy improves patient outcomes; every hour delay of effective antibiotic therapy increases mortality by almost 8% in patients with septic shock.1 A positive T2Bacteria or T2Candida test result may enable rapid targeted treatment and prevent a serious bloodstream infection from progressing to sepsis.
Contact us to learn how T2Direct Diagnostics can help your hospital institution!
Schedule a meeting with our PharmDs to Learn More!
1. Kumar A, et al. Critical Care Medicine, 2006
2. Patch ME, at al. Journal of Antimicrobial Chemotherapy, 2018
3. Wilson N, et al. Journal of Antimicrobial Stewardship, 2017
4. Shields RK, et al. Incorporating T2Candida Testing into Rational Antifungal Management. Poster Presentation, ID Week 2018
5. Bilir SP, et al. Future Microbiology, 2015
FDA-cleared, direct-from-blood diagnostic tools:
Over 200 studies published in peer-reviewed journals have featured T2MR in a breadth of applications